Proton Pump Inhibitors
Drug Safety Updates
April 2012 : Prolonged use of proton pump inhibitors (PPIs) has been associated with hypomagnesaemia - consider checking magnesium levels before starting treatment and repeat measurements periodically during treatment.
April 2012: Long-term use of PPIs has also been linked to fracture.
September 2015: Proton pump inhibitors are associated with infrequent cases of subacute cutaneous lupus erythematosus.
NICE Guidance
CG184: Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management, September 2014 (updated October 2019)
CG141: Acute upper gastrointestinal bleeding in over 16s: management, June 2012 (updated August 2016)
Local Guidance
See here for K&M ICB position statements on the use of omeprazole oral suspension for adults or paediatrics in primary care.
GORD patients with simple reflux should be encouraged to make healthy lifestyle changes eg weight loss, avoid large fatty meals and raise the head of the bed at night. Patients with GORD should be given full dose PPI for 2 months . If symptoms recur and in complicated reflux long term maintenance should be considered.
PPIs should be prescribed for appropriate indications at the lowest effective dose for the shortest period; the need for long-term treatment should be reviewed periodically.
Intravenous PPI is used for patients with confirmed upper GI bleeding and those with endoscopic evidence of recurrent haemorrhage. PPIs should not be used prior to diagnosis by endoscopy in patients with upper GI bleeding.
OTC pack sizes available may be different to the pack sizes listed here.
Choices for dispersible tablets:
Omeprazole dispersible tablets are the first choice PPI for children (>1 year and >10kg) who cannot swallow the capsules in both hospital and community.
For adult patients with swallowing difficulty the first choice PPI is omeprazole dispersible for community and lansoprazole dispersible for hospital.
In some instances, it is more appropriate for patients to remain on the unlicensed indication of omeprazole oral solution. Please discuss with local paediatrician.
| Pack |
|---|
| 28 capsule |
First choice PPI for children (>1 year and >10kg) who cannot swallow the capsules.
Community first choice PPI for adult patients with swallowing difficulty.
| Pack |
|---|
| 28 tablet (4 x 7 tablets) |
| Pack |
|---|
| 14 capsule |
| 28 capsule |
First choice PPI for children (>1 year and >10kg) who cannot swallow the capsules.
Community first choice PPI for adult patients with swallowing difficulty.
| Pack |
|---|
| 28 tablet (4 x 7 tablets) |
| Pack |
|---|
| 28 capsule |
| 7 capsule |
First choice PPI for children (>1 year and >10kg) who cannot swallow the capsules.
Community first choice PPI for adult patients with swallowing difficulty.
| Pack |
|---|
| 7 tablet |
Unlicensed omeprazole suspensions for paediatric use only.
In some circumstances secondary care may use unlicensed omeprazole suspensions.
| Pack |
|---|
| 75 ml |
Unlicensed omeprazole suspensions for paediatric use only.
In some circumstances secondary care may use unlicensed omeprazole suspensions.
| Pack |
|---|
| 75 ml |
Unlicensed omeprazole oral solution for paediatric use only.
In some circumstances secondary care may use unlicensed omeprazole suspensions.
| Pack |
|---|
| 1 ml |
| Pack |
|---|
| 5 vial |
| Pack |
|---|
| 14 capsule |
| 28 capsule |
| 56 capsule |
Hospital first choice PPI for adult patients with swallowing difficulty.
| Pack |
|---|
| 28 tablet |
| Pack |
|---|
| 14 capsule |
| 28 capsule |
| 56 capsule |
| 7 capsule |
Hospital first choice PPI for adult patients with swallowing difficulty.
| Pack |
|---|
| 14 tablet |
| 28 tablet |
| 7 tablet |
| Pack |
|---|
| 14 tablet |
| 28 tablet |
| 7 tablet |
| Pack |
|---|
| 14 tablet |
| 28 tablet |
| Pack |
|---|
| 5 vial |
| 1 vial |
| Pack |
|---|
| 28 capsule |
| Pack |
|---|
| 28 capsule |
| Pack |
|---|
| 28 capsule |
| Pack |
|---|
| 28 capsule |
| Pack |
|---|
| 28 sachet |
| Pack |
|---|
| 1 vial |
| 10 vial |
- On Formulary Preferred
- On Formulary Second Line
- On Formulary Third Line
- Specialist Initiation
- Secondary Care Only
- Not Approved for Formulary

